As companies mature, in our Long-term Islet we transition to more passive ownership, balancing our portfolio with new investments while realizing gains from mature holdings.
Unique enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals.
Dedicated to creating regenerative implants for improved healing of bone defects.
Replacing animal testing with best-in-class in vitro technology.